Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib maintenance after first-line remission in advanced epithelial ovarian cancer
ChiCTR1900021912Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Apr 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR1900021912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021912.